Harvard End Period Cash Flow vs Begin Period Cash Flow Analysis

HBIO Stock

USD 2.20 0.01 0.46%

Harvard Bioscience financial indicator trend analysis is much more than just examining Harvard Bioscience latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Harvard Bioscience is a good investment. Please check the relationship between Harvard Bioscience End Period Cash Flow and its Begin Period Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.

End Period Cash Flow vs Begin Period Cash Flow

End Period Cash Flow vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Harvard Bioscience End Period Cash Flow account and Begin Period Cash Flow. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Harvard Bioscience's End Period Cash Flow and Begin Period Cash Flow is 0.84. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Harvard Bioscience, assuming nothing else is changed. The correlation between historical values of Harvard Bioscience's End Period Cash Flow and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Harvard Bioscience are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of End Period Cash Flow i.e., Harvard Bioscience's End Period Cash Flow and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

End Period Cash Flow

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Harvard Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Harvard Bioscience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.At this time, Harvard Bioscience's Selling General Administrative is very stable compared to the past year. As of the 29th of November 2024, Tax Provision is likely to grow to about 1.1 M, while Discontinued Operations is likely to drop about 1.3 M.

	2021	2022	2023	2024 (projected)
Gross Profit	67.7M	60.8M	66.1M	48.5M
Total Revenue	118.9M	113.3M	112.3M	96.8M

Gross Profit Total Revenue

Harvard Bioscience fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Property Plant And Equipment Gross	Short Term Debt	Intangible Assets
Total Assets		0.79	0.58	0.29	0.03	0.29	0.89	0.91	0.81	0.9	0.72	0.24	0.7	0.45	-0.7	0.58	0.97	0.41	0.81	0.86	0.77	0.87	0.0	0.29	0.15	0.78
Total Stockholder Equity	0.79		0.02	0.64	0.22	0.64	0.68	0.78	0.29	0.95	0.16	-0.2	0.22	0.38	-0.41	0.49	0.63	0.15	0.84	0.69	0.23	0.61	0.17	0.04	0.41	0.46
Net Debt	0.58	0.02		-0.5	-0.33	-0.5	0.6	0.49	0.88	0.25	0.89	0.66	0.84	0.33	-0.77	0.36	0.72	0.44	0.27	0.55	0.87	0.64	-0.17	0.64	-0.21	0.62
Cash	0.29	0.64	-0.5		0.5	1.0	0.02	0.15	-0.15	0.53	-0.18	-0.53	-0.3	-0.03	0.31	-0.08	0.13	-0.11	0.25	0.04	-0.14	-0.09	0.02	-0.39	0.45	0.13
Other Assets	0.03	0.22	-0.33	0.5		0.5	-0.01	-0.02	-0.17	0.17	-0.16	-0.18	-0.13	-0.18	0.18	-0.47	-0.06	0.22	-0.12	-0.04	-0.19	-0.08	0.04	-0.13	0.28	-0.33
Cash And Short Term Investments	0.29	0.64	-0.5	1.0	0.5		0.02	0.15	-0.15	0.53	-0.18	-0.53	-0.3	-0.03	0.31	-0.08	0.13	-0.11	0.25	0.04	-0.14	-0.09	0.02	-0.39	0.45	0.13
Common Stock Shares Outstanding	0.89	0.68	0.6	0.02	-0.01	0.02		0.98	0.75	0.8	0.63	0.42	0.79	0.57	-0.88	0.65	0.86	0.38	0.78	0.99	0.66	0.96	0.07	0.47	0.03	0.51
Other Stockholder Equity	0.91	0.78	0.49	0.15	-0.02	0.15	0.98		0.68	0.88	0.54	0.31	0.68	0.56	-0.83	0.69	0.84	0.3	0.86	0.98	0.59	0.93	0.09	0.38	0.07	0.54
Total Liab	0.81	0.29	0.88	-0.15	-0.17	-0.15	0.75	0.68		0.5	0.98	0.56	0.89	0.34	-0.71	0.45	0.92	0.5	0.48	0.69	0.99	0.78	-0.15	0.42	-0.16	0.78
Total Current Assets	0.9	0.95	0.25	0.53	0.17	0.53	0.8	0.88	0.5		0.37	-0.02	0.42	0.39	-0.59	0.54	0.76	0.17	0.86	0.8	0.44	0.75	0.01	0.16	0.34	0.55
Short Long Term Debt Total	0.72	0.16	0.89	-0.18	-0.16	-0.18	0.63	0.54	0.98	0.37		0.56	0.85	0.31	-0.6	0.32	0.85	0.49	0.32	0.57	0.98	0.66	-0.21	0.42	-0.16	0.75
Other Current Liab	0.24	-0.2	0.66	-0.53	-0.18	-0.53	0.42	0.31	0.56	-0.02	0.56		0.79	0.41	-0.6	0.31	0.37	0.42	0.17	0.41	0.48	0.42	0.08	0.4	-0.7	0.17
Total Current Liabilities	0.7	0.22	0.84	-0.3	-0.13	-0.3	0.79	0.68	0.89	0.42	0.85	0.79		0.55	-0.8	0.48	0.79	0.56	0.46	0.76	0.8	0.79	-0.04	0.56	-0.25	0.5
Property Plant And Equipment Net	0.45	0.38	0.33	-0.03	-0.18	-0.03	0.57	0.56	0.34	0.39	0.31	0.41	0.55		-0.52	0.55	0.44	0.09	0.43	0.67	0.23	0.51	0.08	0.42	0.0	0.22
Retained Earnings	-0.7	-0.41	-0.77	0.31	0.18	0.31	-0.88	-0.83	-0.71	-0.59	-0.6	-0.6	-0.8	-0.52		-0.59	-0.71	-0.3	-0.59	-0.88	-0.62	-0.84	0.01	-0.71	0.09	-0.4
Accounts Payable	0.58	0.49	0.36	-0.08	-0.47	-0.08	0.65	0.69	0.45	0.54	0.32	0.31	0.48	0.55	-0.59		0.55	0.16	0.73	0.68	0.37	0.71	0.15	0.22	-0.25	0.47
Non Current Assets Total	0.97	0.63	0.72	0.13	-0.06	0.13	0.86	0.84	0.92	0.76	0.85	0.37	0.79	0.44	-0.71	0.55		0.51	0.71	0.82	0.89	0.85	0.0	0.35	0.04	0.84
Non Currrent Assets Other	0.41	0.15	0.44	-0.11	0.22	-0.11	0.38	0.3	0.5	0.17	0.49	0.42	0.56	0.09	-0.3	0.16	0.51		0.22	0.3	0.46	0.42	0.53	0.29	-0.1	0.27
Net Receivables	0.81	0.84	0.27	0.25	-0.12	0.25	0.78	0.86	0.48	0.86	0.32	0.17	0.46	0.43	-0.59	0.73	0.71	0.22		0.78	0.41	0.8	0.23	-0.01	-0.01	0.61
Common Stock Total Equity	0.86	0.69	0.55	0.04	-0.04	0.04	0.99	0.98	0.69	0.8	0.57	0.41	0.76	0.67	-0.88	0.68	0.82	0.3	0.78		0.59	0.93	0.07	0.47	0.04	0.48
Non Current Liabilities Total	0.77	0.23	0.87	-0.14	-0.19	-0.14	0.66	0.59	0.99	0.44	0.98	0.48	0.8	0.23	-0.62	0.37	0.89	0.46	0.41	0.59		0.7	-0.2	0.36	-0.14	0.82
Inventory	0.87	0.61	0.64	-0.09	-0.08	-0.09	0.96	0.93	0.78	0.75	0.66	0.42	0.79	0.51	-0.84	0.71	0.85	0.42	0.8	0.93	0.7		0.05	0.39	-0.03	0.56
Other Current Assets	0.0	0.17	-0.17	0.02	0.04	0.02	0.07	0.09	-0.15	0.01	-0.21	0.08	-0.04	0.08	0.01	0.15	0.0	0.53	0.23	0.07	-0.2	0.05		-0.12	-0.15	-0.1
Property Plant And Equipment Gross	0.29	0.04	0.64	-0.39	-0.13	-0.39	0.47	0.38	0.42	0.16	0.42	0.4	0.56	0.42	-0.71	0.22	0.35	0.29	-0.01	0.47	0.36	0.39	-0.12		0.17	0.03
Short Term Debt	0.15	0.41	-0.21	0.45	0.28	0.45	0.03	0.07	-0.16	0.34	-0.16	-0.7	-0.25	0.0	0.09	-0.25	0.04	-0.1	-0.01	0.04	-0.14	-0.03	-0.15	0.17		-0.06
Intangible Assets	0.78	0.46	0.62	0.13	-0.33	0.13	0.51	0.54	0.78	0.55	0.75	0.17	0.5	0.22	-0.4	0.47	0.84	0.27	0.61	0.48	0.82	0.56	-0.1	0.03	-0.06

Click cells to compare fundamentals

Harvard Bioscience Account Relationship Matchups

Harvard Bioscience fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	164.9M	156.3M	162.3M	145.4M	137.4M	124.6M
Total Stockholder Equity	81.7M	76.7M	83.4M	72.2M	73.1M	82.7M
Net Debt	45.5M	39.7M	40.5M	42.3M	38.5M	40.4M
Cash	8.3M	8.3M	7.8M	4.5M	4.3M	4.1M
Other Assets	2.3M	8.9M	12.3M	7.8M	8.9M	5.2M
Cash And Short Term Investments	8.3M	8.3M	7.8M	4.5M	4.3M	4.1M
Common Stock Shares Outstanding	37.8M	38.6M	40.3M	41.4M	42.4M	33.1M
Liabilities And Stockholders Equity	164.9M	156.3M	162.3M	145.4M	137.4M	124.6M
Other Stockholder Equity	218.5M	221.7M	225.7M	229.0M	232.4M	193.5M
Total Liab	83.2M	79.6M	78.9M	73.1M	64.3M	41.9M
Total Current Assets	53.6M	51.7M	61.6M	51.1M	49.0M	53.5M
Short Long Term Debt Total	53.8M	48.0M	48.3M	46.8M	42.8M	22.7M
Other Current Liab	9.1M	7.2M	10.5M	7.5M	12.3M	6.2M
Total Current Liabilities	25.3M	21.1M	25.3M	23.2M	26.5M	17.5M
Property Plant And Equipment Net	4.8M	4.0M	3.4M	3.4M	8.8M	4.9M
Retained Earnings	(124.6M)	(132.4M)	(132.7M)	(142.2M)	(145.6M)	(152.9M)
Accounts Payable	5.3M	6.0M	4.9M	6.4M	5.6M	5.7M
Non Current Assets Total	111.3M	104.6M	100.8M	94.2M	88.3M	73.6M
Non Currrent Assets Other	10.7M	8.9M	12.3M	13.6M	6.5M	4.1M
Net Receivables	20.7M	17.8M	21.8M	16.7M	16.1M	18.5M
Common Stock Total Equity	438K	444K	452K	454K	522.1K	407.4K
Non Current Liabilities Total	57.9M	58.5M	53.6M	49.9M	37.8M	25.8M
Inventory	22.1M	22.3M	27.6M	26.4M	24.7M	19.3M
Other Current Assets	2.5M	3.4M	4.3M	3.5M	3.9M	6.2M
Property Plant And Equipment Gross	13.2M	11.7M	3.4M	24.0M	23.1M	24.3M
Accumulated Other Comprehensive Income	(12.7M)	(13.1M)	(10.0M)	(15.1M)	(14.2M)	(13.5M)
Short Term Debt	6.9M	3.8M	5.4M	5.9M	8.7M	9.1M
Intangible Assets	38.4M	33.2M	27.4M	21.0M	16.0M	21.5M
Common Stock	438K	444K	452K	454K	434K	410.2K
Long Term Debt	46.9M	46.3M	45.1M	43.0M	30.7M	20.7M
Good Will	57.4M	58.6M	57.7M	56.3M	57.1M	46.4M
Property Plant Equipment	4.8M	4.0M	3.4M	3.4M	3.0M	3.5M
Current Deferred Revenue	3.9M	3.8M	4.3M	3.4M	7.7M	8.1M
Other Liab	2.1M	12.2M	8.5M	1.6M	1.8M	1.7M
Net Tangible Assets	24.3M	(15.1M)	83.4M	72.2M	65.0M	68.2M
Retained Earnings Total Equity	(124.6M)	(132.4M)	(132.7M)	(142.2M)	(128.0M)	(134.4M)
Long Term Debt Total	9.0M	58.8M	46.9M	46.3M	53.2M	30.0M
Capital Surpluse	229.2M	232.4M	225.7M	229.0M	263.4M	239.3M
Deferred Long Term Liab	2.3M	2.0M	1.9M	590K	678.5K	644.6K

When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock:

How To Invest In Harvard

Details

Is Harvard Stock a good investment?

Details

What is Harvard Bioscience's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.

You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.80)

Earnings Share

(0.33)

Revenue Per Share

2.258

Quarterly Revenue Growth

(0.13)

Return On Assets

(0.02)

The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Harvard End Period Cash Flow vs Begin Period Cash Flow Analysis

End Period Cash Flow vs Begin Period Cash Flow

End Period Cash Flow vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Begin Period Cash Flow

Harvard Bioscience fundamental ratios Correlations

Harvard Bioscience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Harvard Bioscience fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock Total Equity	+ 0.99	Common Stock Shares Outstanding
Non Current Liabilities Total	+ 0.99	Total Liab
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding
Common Stock Total Equity	+ 0.98	Other Stockholder Equity
Short Long Term Debt Total	+ 0.98	Total Liab

Common Stock Total Equity	- 0.88	Retained Earnings
Retained Earnings	- 0.88	Common Stock Shares Outstanding
Inventory	- 0.84	Retained Earnings
Retained Earnings	- 0.83	Other Stockholder Equity
Retained Earnings	- 0.8	Total Current Liabilities
Retained Earnings	- 0.77	Net Debt